Cryopreserved, transiently transfected HepG2 cells were compared to freshly transfected HepG2 cells for use in a pregnane X receptor (PXR) transactivation assay. Assay performance was similar for both cell preparations; however, cryopreserved cells demonstrated less interassay variation. Validation with drugs of different PXR activation potencies and efficacies demonstrated an excellent correlation (r 2 > 0.95) between cryopreserved and fresh cells. Cryopreservation did not change the effect of known CYP3A4 inducers that have poor cell permeability, indicating that cryopreservation had little effect on membrane permeability. In addition, cryopreserved HepG2 cells did not exhibit enhanced susceptibility to cytotoxic compounds compared to transiently transfected control cells. The use of cryopreserved cells enables this assay to run with enhanced efficiency. (Journal of Biomolecular
INTRODUCTION
P REGNANE X RECEPTOR (PXR) is a nuclear hormone receptor that, when activated by an agonist, can act as a transcription factor and induce transcription of cytochrome P450 (CYP) 3A4. CYP3A4 plays a major role in metabolizing many clinically prescribed drugs. 1 Compounds that activate PXR have the potential risk of causing overexpression of CYP3A4 and thus drug-drug interaction by increasing the metabolic clearance of coadministered CYP3A4 substrates. 2 Previously, we described a cell-based reporter assay that has been used to evaluate the PXR activation potential of discovery or development of drug candidates. 3 In this original assay, we used HepG2 cells transiently transfected with both a PXR expression vector and a luciferase reporter plasmid containing a partial CYP3A4 promoter. This assay supports the medicinal chemistry efforts of eliminating the potential liability of PXR activation for various drug discovery programs. However, dependence of this assay on large quantities of cells with consistent transfection efficiency has posed a major challenge for long-term assay precision. With the increasing demand for large quantities of transfected cells for high-throughput screening (HTS), various groups have explored the possibility of using cryopreserved cells for HTS. [4] [5] [6] In an effort to perform this assay efficiently, we have investigated the use of cryopreserved, transiently transfected cells in a PXR transactivation assay.
The ability to scale, pool, freeze, and control large batches of transiently transfected cells for assay use represents a process improvement not only for HTS assays but also for other secondary assays that support medicinal chemistry efforts. Cryopreservation of transfected cells decreases the time required to perform assays by reducing the time spent transiently transfecting cells. Therefore, reducing the assay to data cycle time enables chemists to make synthetic decisions more rapidly and thus facilitates the lead optimization process. By disconnecting the dependency of the assay from continuous cell production, any delays in the screening of compounds due to technical issues associated with culturing live cells can be avoided and significant increases in assay demand by large chemistry libraries can be effectively managed.
The cell-based PXR transactivation assay uses transformed human hepatocyte cells (HepG2). The use of cryopreserved primary human hepatocytes is well established. [7] [8] [9] [10] [11] [12] [13] In these studies, the ability of inducers of CYP enzymes (rifampicin, rifabutin, and omeprazole) to induce CYP enzymes was not affected by cryopreservation. However, the use of cryopreserved HepG2 cells has not been thoroughly studied. So in this report, we compare cryopreserved HepG2 cells in a PXR transactivation assay with cells maintained in continuous culture.
MATERIALS AND METHODS

Materials
Dulbecco's Modified Eagle's Medium (DMEM), Lipofectamine 2000, phosphate-buffered saline (PBS), trypsin-ethylenediamine tetraacetic acid (EDTA) (0.25%), and penicillin-streptomycin were purchased from GIBCO/Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from Hyclone (Logan, UT). HepG2 and Caco-2 cells were obtained from the American Type Culture Collection (Rockville, MD). Human PXR-pcDNA3 and luciferase reporter containing CYP3A4 promoter (CYP3A-Luc) were generated as described previously. 3 Black standard 384-well plates, black clear-bottom tissue culture-treated 384-well plates, and conical tubes were purchased from BD Biosciences (Lexington, KY). HTS-Transwell inserts (0.33 cm 2 for 24 wells) with a polycarbonate membrane (0.4-mm pore size) were purchased from Costar (Cambridge, MA). Luciferase substrate (Steady-Glo) was purchased from Promega (Madison, WI). Alamar Blue was purchase from Trek Diagnostics (Chicago, IL). Hank's balanced salt solution (HBSS), N-(2-hydroxyethyl) piperazine-N′-2-ethanesulfonic acid (HEPES), rifampicin, mifepristone, sulfinpyrazone, troglitazone, reserpine, mevastatin, omeprazole, lansoprazole, nifedipine, metyrapone, tamoxifen, prednisone, theophylline, perhexaline, nortriptylene, chlorpromazine, ketoconazole, fluoxetine, and DMSO were purchased from Sigma (St. Louis, MO). SR12813 was synthesized at Bristol-Myers Squibb (BMS).
PXR transactivation assay using cryopreserved and freshly transfected cells
In general, the protocol of Zhu and others was followed. 3 The culture of HepG2 cells was performed in T175 flasks using DMEM containing 10% charcoal/dextran-treated FBS. The transfection mixture contained 1 µg/ml of PXR-pcDNA3 plasmid DNA, 20 µg/ml of CYP3A-Luc plasmid DNA, 90 µl/ml of Lipofectamine 2000, and serum-free medium. After incubating at room temperature for 20 min, the transfection mixture (1 ml per flask) was applied to the cells in fresh medium (20 ml per flask), and the flasks were incubated at 37 °C (5% CO 2 , 95% humidity) overnight.
Cells in each flask were washed with PBS and trypsinized in 5 ml of trypsin-EDTA (0.25%) for 10 min at 37 °C, the flasks were tapped vigorously, and the cells were pipetted up and down to break up aggregates. After the addition of 5 ml of DMEM containing 10% charcoal/dextran-treated FBS, the entire mixture was transferred to conical tubes and allowed to settle for 45 s, and the supernatant with cells was withdrawn cell aggregates and debris were left (exact 45 s is critical: too long may cause cell loss due to cell precipitation, and too short may cause cell aggregates and debris still mixed with cells). The supernatant was then centrifuged at 1500 rpm (514g) for 4 minutes, and the subsequent supernatant was discarded.
An optimal cryopreservation protocol was used (see the Discussion section) in which the cell pellets of 20 million cells were resuspended in 3 ml of DMEM containing 20% charcoal/dextran-treated FBS and 10% DMSO in conical tubes (BD Biosciences). 2 The conical tubes were placed in a styrofoam rack and stored at -80 °C. The insulation of styrofoam ensured a slow freezing process required for the optimal cryopreservation. To resurrect cryopreserved cells, the conical tubes were incubated at 37 °C with agitation for 20 min, the cells were centrifuged at 1500 rpm for 4 min, and the supernatant (the cryopreservation medium) was discarded.
For both cryopreserved and freshly transfected cells, cell pellets were resuspended in DMEM containing 5% charcoal/ dextran-treated FBS and penicillin-streptomycin (100 U/ml penicillin and 100 µg/ml streptomycin), and the concentration was adjusted to 0.33 million cells/ml. Forty-five microliters of cell mixture was added to each well of a black standard 384-well plate with 5 µl of test compound dissolved in 5% DMSO solution. The plates were incubated at 37 °C (5% CO 2 ) overnight before 25 µl of luciferase substrate (Steady-Glo, Promega) was added to each well. After 30 min, the plates were read on a Packard Topcount plate reader.
Data processing
Compounds were tested at 10 concentrations (50.0, 16.7, 5.56, 1.85, 0.617, 0.206, 0.0686, 0.0229, 0.00762, 0.00254 µM). Rifampicin (10 µM) was included in each plate as an internal standard and positive control. Raw data were normalized against the rifampicin response at 10 µM and then expressed as percentage activation (%Act) at each concentration: where the total signal was the signal from the 10 µM rifampicin and the blank signal was from the DMSO vehicle. Curve-fitting software, XL-Fit (IDBS, Inc., Emeryville, CA) was used to fit the concentration response curve and generate the 4 parameters of the Hill equation in logarithmic format. Maximum activation (Max %Act) and concentration at 50% activation (EC 50 ) were reported. To assess assay performance, rifampicin was added to columns 1 through 22 (total wells, final concentration in the assay: 10 µM) and DMSO vehicle to columns 23 and 24 (blank wells) of 384-well plates. The statistical parameter Z′ was calculated based on total and blank signals. 14 When comparing cryopreserved with freshly transfected cells, Excel (Microsoft, Redmond WA)) was used to calculate the Pearson correlation coefficient r 2 , and ANOVA (single-factor analysis tool) was used to calculate the p-value. Following convention, a p-value of less than 0.05 was considered statistically significant. [15] [16] [17] 
Cytotoxicity assay of HepG2 cells
HepG2 cells were prepared as described above and diluted to 1.8 × 10 5 cells/ml. Forty-five microliters of cell mixture was added to each well of black, clear-bottom, tissue culture-treated, 384-well plates with 5 µl of test compound dissolved in 5% DMSO solution. Plates were incubated at 37 °C (5% CO 2 , 95% humidity) for 24 h, followed by the addition of 5 µl of Alamar Blue reagent to each well. Plates were then incubated for an additional 4 hours at 37 °C, 5% CO 2 , after which the fluorescence was measured at Ex535/Em590. Compounds were tested at the same 10 concentrations as in the PXR assay, and XL-Fit (IDBS, Inc.) was used for curve-fitting and CC 50 determination, where CC 50 is the concentration producing 50% cytotoxicity.
Caco-2 permeability assay
Caco-2 cells were seeded onto filter membranes at a density of about 8 × 10 5 cells/cm 2 for 24-well plates. The cells were grown in DMEM containing 10% FBS, 100 U/ml penicillin-G, and 100 mg/ml streptomycin. The culture medium was replaced every 2 days, and the cells were maintained at 37 °C (5% CO 2 , 95% humidity). Permeability studies were conducted with the monolayers cultured for approximately 21 days with the cell passage numbers between 20 and 40. Physiologically and morphologically well-developed Caco-2 cell monolayers with transepithelial electrical resistance values greater than 400 ohms cm 2 were used for the studies reported in this article.
The transport medium used for the studies was modified HBSS buffer containing 10 mM HEPES. The pH of the apical compartment was 6.5, and the pH for the basolateral compartments was 7.4. Prior to all experiments, each monolayer was washed twice with pH 6.5 buffer, and the transepithelial electrical resistance was measured to ensure the integrity of the monolayers. The concentration of test compounds was typically 200 µM in this assay. All 6 compounds tested here were soluble at 200 µM. The permeability studies were initiated by adding an appropriate volume of buffer containing test compound to the apical (for apical to basolateral transport; A to B) side of the monolayer. Apical and basolateral volumes were 0.2 and 1.1 ml, respectively, in the 24-well plates. The monolayers were then placed in an incubator for 4 h at 37 °C. Samples were taken from both the apical and basolateral compartment at the end, and the concentrations of test compound were analyzed by a high-performance liquid chromatography method. The permeability coefficient (Pc) was calculated according to the equation
where dA/dt is the flux of the test compound across the monolayer (nmol/s), S is the surface area of the cell monolayer, and C o is the initial concentration (200 µM) in the donor compartment. The Pc values were expressed as nm/s. Compounds with Pc values less than 100 nm/s are generally regarded as low permeable. 18 The detection limit was 15 nm/s.
RESULTS
Assay performance comparison using cryopreserved versus freshly transfected cells
The transfected HepG2 cells with 10% DMSO were stored in conical tubes. These conical tubes were placed in a styrofoam rack and stored at -80 °C to achieve a slow freezing process required for the optimal cryopreservation. After 1 to 4 weeks, the conical tubes were resurrected quickly at 37 °C. The cryopreserved cells were tested in the PXR transactivation assay, and responses were compared to freshly transfected cells.
A standard PXR agonist, rifampicin (10 µM), was used to generate and define a maximal activation signal (total signal), whereas the DMSO vehicle was used to generate a background signal (blank signal). The results are summarized in Table 1 . Over the 4-week period, for both cryopreserved and fresh cells, the activation signal (total signal) varied within a range of about 3-fold (cryopreserved cells: 12,097 ± 5195 cps; fresh cells: 23,313 ± 8858 cps), and the background signal (blank signal) also varied within a range of about 3-fold (cryopreserved cells: 1485 ± 779 cps; fresh cells: 1545 ± 703 cps). These data reflected normal run-to-run assay variation, which we have observed over the course of 2 years of assay performance. Generally, the activation by 10 µM rifampicin in cryopreserved cells was lower than fresh cells (the average fold induction for fresh cells was 15.4, but that of cryopreserved cells was 8.5), indicating that the cryopreservation process had some effects on the assay. Nevertheless, the assay performance as determined by the Z′ value was still acceptable (Z′ > 0.5). The variation around the total signal (10 µM rifampicin) and blank signal (DMSO vehicle) was comparable between cryopreserved and freshly transfected cells (total signal, coefficient of variation [CV] of cryopreserved cells: 10.5%-10.8%, CV of fresh cells: 7.4%-10.6%; blank signal, CV of cryopreserved cells: 11.8%-21.9%, CV of fresh cells: 7.0%-18.0%).
Although the fold induction for cryopreserved cells was lower than for fresh cells, it was more consistent from run to run (7-to 10-fold) versus freshly transfected cells (12-to 20fold). This may be explained by the fact that cryopreserved cells used in the PXR transactivation assay were all from a single batch of transfection, whereas fresh cells used in the PXR transactivation assay were transfected in different batches with varying transfection efficiencies.
Validation with drugs
In the PXR transactivation assay, compound potency is measured as EC 50 and efficacy is measured as Max %Act. All data were normalized to the activation signal generated by 10 µM rifampicin (100% activation). As these data are used to predict the induction potential of CYP3A4 for drug metabolism in humans, a thorough pharmacological characterization of drugs that induce CYP3A4 in vivo has been reported. 19 Twenty-seven pharmaceutical compounds that exhibited a wide range of PXR activation potencies were selected for the validation study. As shown in Table 2 , EC 50 values of these 27 drugs were compared, and the correlation analysis gave an r 2 value of 0.98 (p < 0.001; p-value of less than 0.05 was considered as statistically significant [15] [16] [17] ), indicating an excellent correlation between cryopreserved and freshly transfected cells. Thus, the cryopreservation process did not change the PXR activation potential of these transiently transfected HepG2 cells. Likewise, the efficacy values (Max %Act) obtained using cryopreserved versus freshly transfected cells for these 27 drugs correlated with an r 2 value of 0.92 (p < 0.001). Therefore, cryopreserved transfected cells exhibited similar predictions for clinical CYP induction as freshly transfected cells.
To investigate the effect of storage time on cryopreserved HepG2 cells, 4 drugs of different PXR activation potency, SR12813, rifampicin, mifepristone, and sulfinpyrazone, were selected, and their potency and efficacy were examined in cells that had been cryopreserved for up to 4 weeks. The EC 50 and Max %Act values of cryopreserved and fresh cells are shown in Table 1 . In the 4-week period, the r 2 values for EC 50 and Max %Act remained at >0.99 (p < 0.001) and 0.98 (p < 0.02), respectively. It indicates that the good correlation between using cryopreserved and freshly transfected cells remained unchanged over a 4-week period.
PXR agonists with low cell permeability
One concern for the use of cryopreserved transiently transfected cells was that cell membrane permeability may be altered and thus the potency and efficacy of PXR agonists may change. Seven poorly permeable BMS compounds were selected to investigate this possibility. All compounds exhibited PXR activation yet were poorly permeable, as assessed by Caco-2 permeability measurements, which could be caused by either low passive permeability or transporter (i.e., P-glycoprotein). 18 Their permeability coefficients (Pc) were all lower than 15 nm/s (the detection limit of the Caco-2 assay), similar to the well-characterized low-permeable drug mannitol. 20 A change in membrane permeability, due to cryopreservation, would be expected to affect the potency and efficacy of compounds in the PXR transactivation assay. As shown in Table 2 , there was a good correlation between EC 50 (r 2 = 0.95, p < 0.001) and Max %Act (r 2 = 0.96, p < 0.001) values using cryopreserved and fresh transiently transfected cells for these 7 poorly permeable compounds. These data suggest that HepG2 cell membrane permeability was relatively unaffected by the cryopreservation process.
Cytotoxicity
When cells are cryopreserved, the cell membrane may be damaged (see the Discussion section) and cause enhanced susceptibility to cytotoxic agents. The resulting cell death may cause false negatives in the PXR assay. A mitochondrial redox dye (Alamar Blue)-based assay was used in this study to measure cytotoxicity. Because compounds used in this study all exhibit either no cytotoxicity or very low cytotoxicity for both cryopreserved and fresh HepG2 cells, another 27 compounds that showed cytotoxicity against other cell lines (HEK293 and immortalized hepatic parenchymal cells) were tested in a cytotoxicity assay using cryopreserved cells and freshly transfected cells. Table 3 shows that all 15 compounds showed similar CC 50 values (concentration of compound causing 50% cell death) in both cell preparations (r 2 = 0.92, p < 0.001). Therefore, cryopreservation did not appear to markedly alter sensitivity to cytotoxic agents.
DISCUSSION
Cell-based assays are beginning to replace traditional isolated target-based assays using enzyme or subcellular fractions in high-throughput drug discovery screening and drug development because of the native environment of the target protein in cells and the ability to recapitulate and predict in vivo outcomes. Immortalized and primary cell models are commonly employed in the pharmaceutical industry for a variety of assays. These cellular systems can function as stand-alone cell-based assays or as vehicles for transient or stable expression of proteins and/or reporter complexes. For example, primary human hepatocytes are the gold standard assay to predict CYP3A4 enzyme induction and serve as a stand-alone cell-based assay. However, this system requires scarce primary cellular reagents, limiting its utility for testing large number of compounds. In contrast, the PXR transactivation assay is of higher throughput and thus well suited for a large compound capacity, serving as an example of a cell-based assay in which the HepG2 cells function as a vehicle for transfected proteins, although it is only one of the mechanisms of CYP3A4 induction. The use of cryopreserved cells has increased our ability to perform assays on a routine basis. For example, the use of primary human hepatocytes is limited by a lack of routine access, donor-to-donor variability, variable quality, and the need to evaluate multiple donors in a timely fashion. These limitations are overcome, in part, by the use of cryopreserved human hepatocytes to assess CYP3A4 induction potential. Cryopreserved human hepatocytes are an acceptable model to predict the induction effect of xenobiotics on CYP3A4 and other P450 enzymes based on concordance with in vivo models of CYP induction. 21 Likewise, we have demonstrated that cryopreserved, transiently transfected HepG2 cells when used in a high-throughput PXR transactivation assay exhibit consistent induction effects of xenobiotics on CYP3A4.
In this study, we examined the potential for using cryopreserved transiently transfected cells in a PXR transactivation assay. We used optimal cryopreservation conditions and compared these cryopreserved cells to those freshly transfected. These data indicate that the transfected HepG2 cells survive and function similarly after resurrection to those maintained in culture. Pharmacological validation using drugs of differing potency and efficacy of PXR activation showed good concordance between cryopreserved and fresh cells. Because EC 50 and efficacies of compounds were similar in both cell populations, the prediction of CYP induction potential was also similar. Although the assay signal and fold induction using cryopreserved cells were lower than fresh cells, the overall assay consistency of response to rifampicin using cryopreserved cells was acceptable (Z′ > 0.5). Although the systematic study was performed only with cells cryopreserved for up to 4 weeks, longer storage is definitely possible based on our results. These observations suggest that cryopreserved cells offer an alternative to the freshly transfected cells that are traditionally used for such assays.
Compared with maintaining cells in continuous culture, bulk cryopreservation provides shorter assay cycle time, a reduction in labor and reagents, and flexible assay scheduling. However, cryopreservation may cause damage to cells or alter their biological response. During freezing, ice crystals can be formed, causing mechanical crushing of cell and nuclear membranes. [22] [23] [24] Furthermore, when ice forms, solutes (salts and proteins) present in the storage medium are excluded from ice crystals and thus concentrated in the remaining liquid phase. This cryo-concentration effect may lead to precipitation of solutes, shifts in pH, and osmotic imbalance, which result in excessive shrinkage and death of cells. 22, [25] [26] [27] Finally, when cryopreserved cells are thawed, smaller ice crystals may dissolve and form larger ice crystals. 28 Damage to cells due to ice crystal formation during cryopreservation can be minimized by various efforts. Studies have shown that ice crystal formation can be reduced by slow freezing. 23, 29 Nonetheless, slow freezing exacerbates the cryoconcentration effect. 30 Successful cryopreservation occurs when the cooling rate is neither too rapid nor too slow. Cell lethality reaches its lowest point when the cooling rate is about 1 °C/min, which can be achieved by placing cryovials in an insulated container. 22, 31, 32 In addition, certain additives (cryoprotectants) to cell medium can attenuate the cryo-concentration effect. Among cryoprotectants, DMSO possesses superior protective capacity with good aqueous solubility and low toxicity. 29, 33, 34 Recrystallization during thawing can be avoided by thawing rapidly in a 37 °C water bath with agitation. 31, 35 Our cryopreservation process included all of these optimized methods and thus resulted in a cell preparation that had similar cellular characteristics to those of fresh transiently transfected cells.
During the cryopreservation process, cell membranes are vulnerable to damage. They may be mechanically damaged by ice crystals, and membrane properties (fluidity, flexibility, strength, and permeability) may be altered by low temperature, shifts in pH, or osmotic imbalance. 22, [25] [26] [27] As a result, the cell membrane permeability of compounds and potential toxic effects may be affected. However, our results using low-permeable PXR activators showed no significant difference in their ability to activate PXR (both efficacy and potency) between cryopreserved and fresh cells. In addition, known cytotoxic agents did not exhibit significantly enhanced effects when comparing cells in the log phase of active growth in continuous culture versus cryopreserved cells after resurrection. These data indicate that the cell membranes were not significantly affected by our cryopreservation process nor was their susceptibility to known cytotoxic agents.
A further advantage of using cryopreserved cells was the uniformity of cell preparations. Cells can be transfected consistently in batches, at the same cell passage, and subjected to the same pharmacologic validation, thereby removing the dayto-day variability in live cell culture and transfection and thus providing consistent assay results.
In this report, we have demonstrated that cryopreserved transiently transfected cells can be used in a PXR transactivation assay without affecting the pharmacological characteristics or the clinical prediction of CYP induction. The cryopreservation process did not appear to affect membrane permeability of the HepG2 cells. Moreover, cells that had been cryopreserved or in continuous culture exhibited little difference to a series of cytotoxic compounds, suggesting no marked difference in cellular physiology. This new approach is advantageous because it offers many technical and logistical benefits: shorter assay time, a reduction in labor and reagents, flexible assay scheduling, and more consistent assay results. Because cell-based reporter assays are widely used in pharmaceutical research, this approach may be applicable to other cell-based high-throughput assays and assays that support medicinal chemistry, including many ADME assays that are crucial for drug discovery programs.
